Trial intelligence / Profile preview

Phase II single-arm study of nimotuzumab plus capecitabine for local residual nasopharyngeal carcinoma after radiotherapy

ChiCTR2500100437Phase 2Not yet recruiting

Sponsor

First Hospital of China Medical University

Start

Apr 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1